News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Guardian Technologies International, Inc. (GDTI.OB): Signature Mapping TBDx(TM) Demonstrates Positive Results


6/21/2010 9:57:44 AM

SAN JOSE, CA--(Marketwire - June 21, 2010) - AmbiCom Holdings, Inc. (OTCBB: ABHI) today announced a four-year exclusive manufacture agreement with a major pharmaceutical and medical device company to supply the WL54-CF Wi-Fi cards for this company's blood glucose meters. The meters are planned to be sold worldwide to hospitals, clinics and other health care facilities for clinicians, nurses and doctors to better monitor glucose levels in patients. The product is currently awaiting FDA approval, and if granted, shipment of the first units could take place as early as the third quarter of 2010.

This blood glucose monitoring system is designed to introduce several technological innovations to help improve patient safety and care and access to data, and enhance system durability at the point of care. AmbiCom is also working with several other departments with this company to supply wireless technologies for future developments.

About AmbiCom
AmbiCom is headquartered in San Jose, California, and is a leading designer and developer of wireless products focusing on the wireless medical industry. The Company's wireless modules and devices are based on the Company's innovative application software for both Wi-Fi and Bluetooth technologies. AmbiCom is committed to wireless design and development of software and hardware, and to bringing new and innovative products to the wireless medical markets and other sectors. The Company plans to grow organically, and to augment that growth by selectively acquiring complementary products and technologies via acquisition opportunities deemed to be of strategic value.

Forward-Looking Statements
This press release contains 'forward-looking statements' within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934. Although the forward-looking statements in this release reflect the good faith judgment of management, forward-looking statements are inherently subject to known and unknown risks and uncertainties that may cause actual results to be materially different from those discussed in these forward-looking statements including, but not limited to, our ability to maintain our website and associated computer systems, our ability generate sufficient market acceptance for our shipping products and services, our inability to generate sufficient operating cash flow, and general economic conditions. Readers are urged to carefully review and consider the various disclosures made by us in the our reports filed with the Securities and Exchange Commission, including those risks set forth in the Company's Current Report on Form 8-K filed on November 13, 2007, which attempt to advise interested parties of the risks and factors that may affect our business, financial condition, results of operation and cash flows. If one or more of these risks or uncertainties materialize, or if the underlying assumptions prove incorrect, our actual results may vary materially from those expected or projected. Readers are urged not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. We assume no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.


Contact:
Beverly Jedynak
Martin E. Janis & Company, Inc.
312-943-1123
Email Contact


Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES